Sign in Subscribe
Cancer research

Monitoring Circulating Tumor DNA Refines Immunotherapy in Lung Cancer Patients

Strategic Insights

— 1 min read

Researchers at the National Cancer Center of China have made a breakthrough in refining and personalizing the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC). A study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) demonstrated that monitoring circulating tumor DNA (ctDNA) can predict survival outcomes and identify patients more likely to benefit from consolidation immune checkpoint inhibitors (ICIs).

Key Takeaways:

  • The study used next-generation sequencing (NGS) with a 139-gene lung cancer panel to assess ctDNA at ultra-deep coverage (30,000 x ) in 177 patients with LS-SCLC treated with chemoradiotherapy (CCRT).
  • Advanced statistical models, including time-dependent Cox regression, were employed to eliminate immortal time bias and accurately predict survival outcomes.
  • Dr. Nan Bi, from the Chinese Academy of Medical Sciences, stated that the study's findings offer a compelling rationale for integrating ctDNA-based stratification in future LS-SCLC trials.
  • The research suggests that ctDNA can help identify patients who are more likely to benefit from consolidation immunotherapy, paving the way for precision immunotherapy in limited-stage SCLC.
  • The study involved 77 patients who received consolidation immune checkpoint inhibitors (ICIs) and were monitored for ctDNA at multiple time points.
  • Dr. Bi noted that early ctDNA detection after induction chemotherapy can help identify patients who are more likely to benefit from consolidation immunotherapy.

Statistics:

  • 177 patients with LS-SCLC were treated with chemoradiotherapy (CCRT) and monitored for circulating tumor DNA (ctDNA).
  • 77 patients received consolidation immune checkpoint inhibitors (ICIs) and were assessed for ctDNA at multiple time points.
  • Ultra-deep coverage (30,000 x ) was used to analyze ctDNA via next-generation sequencing (NGS) with a 139-gene lung cancer panel.
  • Time-dependent Cox regression models were employed to eliminate immortal time bias and predict survival outcomes.

Sources:

  • VerticalNews (2025, September 28)
  • International Association for the Study of Lung Cancer (2025 World Conference on Lung Cancer)
  • National Cancer Center of China
  • Chinese Academy of Medical Sciences

Read more